GLP-1 receptor agonists are four times more likely to resolve MASH (fatty liver inflammation) than placebo, but they do not significantly improve liver fibrosis (scarring).
4x higher MASH resolutionGLP-1 receptor agonists were four times more likely to resolve fatty liver inflammation without worsening scarring (OR 4.04, high-certainty evidence from 25 randomized trials).
What the researchers found
Across 25 randomized controlled trials (n=2,481), GLP-1 receptor agonists significantly increased the resolution of MASH without fibrosis worsening, with an odds ratio of 4.04 (95% CI: 2.69–6.05). However, fibrosis improvement without steatohepatitis worsening did not reach statistical significance.
Subgroup analysis of semaglutide trials showed improved NASH Activity Score (NAS ≥2-point decrease) and steatosis grade but no significant changes in weight, waist circumference, liver enzymes, or lipid levels. Trial sequential analysis confirmed the evidence was sufficient for MASH resolution (required information size = 197 patients reached) but insufficient for fibrosis improvement (required 1,693 patients, not yet reached). GRADE assessment rated the evidence as high certainty for both primary outcomes.
Why it matters
MASH affects millions of people worldwide and is a leading cause of liver transplantation, yet treatment options have been extremely limited until recently. GLP-1 receptor agonists are already widely prescribed for diabetes and obesity, so confirming their liver benefits could help patients with overlapping conditions. However, the finding that fibrosis doesn't improve is crucial — fibrosis is the strongest predictor of liver-related death, meaning GLP-1 drugs alone may not be enough for patients with advanced liver scarring.
How the study worked
This was a PRISMA 2020-compliant systematic review and meta-analysis of 25 randomized controlled trials. Risk of bias was assessed using ROB 2, and evidence certainty was evaluated using the GRADE framework. Trial sequential analysis was performed to check whether enough data existed to draw firm conclusions. Primary outcomes were MASH resolution without fibrosis worsening and fibrosis improvement without steatohepatitis worsening. The protocol was pre-registered in PROSPERO.
What this study cannot tell us
While the meta-analysis included 25 RCTs, the trial sequential analysis showed that insufficient data exists to draw firm conclusions about fibrosis improvement — larger trials are still needed. The included studies varied in GLP-1RA type, dose, duration, and patient population. Liver biopsy, the gold standard for assessing histological outcomes, was not available in all trials. Most trials had relatively short follow-up periods, and MASH and fibrosis are chronic conditions that progress over years to decades.
How to read the evidence
This is a systematic review and meta-analysis of 25 randomized controlled trials — the highest level of clinical evidence. The methodology was rigorous (PRISMA 2020, GRADE, TSA, ROB 2, PROSPERO registration), and evidence certainty was rated high for the primary outcomes.
When this study was published
Published in 2026 with data from 25 RCTs, this is among the most current and comprehensive meta-analyses on GLP-1RAs for MASH. It reflects the latest available clinical trial evidence.
The bigger picture
The treatment landscape for MASH is rapidly evolving. Resmetirom (Rezdiffra) became the first FDA-approved drug specifically for MASH with fibrosis in 2024. GLP-1 receptor agonists, while not specifically approved for MASH, are increasingly recognized for their liver benefits. This meta-analysis clarifies their role: excellent for resolving inflammation but likely needing combination with antifibrotic agents for patients with significant scarring. Future treatment approaches may combine GLP-1RAs with drugs targeting fibrosis directly.
Questions still open
- Would combining GLP-1 receptor agonists with antifibrotic drugs produce better outcomes for patients with both MASH and significant fibrosis?
- How long does the MASH resolution effect persist — does the disease recur if GLP-1 drugs are discontinued?
- Are certain GLP-1RAs (semaglutide vs liraglutide vs others) more effective for liver-specific outcomes?
Common questions
Can GLP-1 drugs like semaglutide treat fatty liver disease?
Why do GLP-1 drugs help with liver inflammation but not scarring?
Read the original research
Impact of Glucagon-Like Peptide-1 Receptor Agonists on Liver-Related Outcomes, Laboratory and Physiologic Parameters in Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Meta-Analysis.
Diabetes, metabolic syndrome and obesity : targets and therapy, 19, 565093
Citation
Wang, Mei-Jun; Jiang, Yu-Nuo; Li, Pei-Pei; Wu, Yuan-Jie. (2026). Impact of Glucagon-Like Peptide-1 Receptor Agonists on Liver-Related Outcomes, Laboratory and Physiologic Parameters in Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Meta-Analysis.. Diabetes, metabolic syndrome and obesity : targets and therapy, 19, 565093. https://doi.org/10.2147/DMSO.S565093